Tevogen Bio (TVGN) News Today $1.34 +0.10 (+8.06%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.32 -0.02 (-1.12%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Tevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral CapitalJune 11 at 2:37 AM | americanbankingnews.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10 at 7:25 PM | nasdaq.comTevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $10.00 price target on shares of Tevogen Bio in a research note on Tuesday.June 10 at 8:14 AM | marketbeat.comRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10 at 4:36 AM | insidertrades.comInsider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of StockTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) CEO Ryan H. Saadi sold 1,438,206 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. This represents a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.June 9 at 9:02 PM | marketbeat.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9 at 9:00 AM | globenewswire.comtevogen bio expands office lease in new jersey with key amendmentJune 5, 2025 | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4, 2025 | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short InterestTevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 1,900,000 shares, a decline of 41.0% from the April 30th total of 3,220,000 shares. Based on an average trading volume of 888,500 shares, the short-interest ratio is currently 2.1 days. Approximately 7.1% of the company's stock are sold short.June 1, 2025 | marketbeat.comTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Tevogen Bio in a report on Tuesday.May 28, 2025 | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comTevogen expands target for COVID treatment to seniorsMay 24, 2025 | investing.comTevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...May 24, 2025 | finanznachrichten.deTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23, 2025 | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23, 2025 | globenewswire.comTevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual MeetingMay 22, 2025 | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Tevogen Bio in a report on Monday.May 14, 2025 | marketbeat.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Tevogen Bio in a report on Tuesday.May 1, 2025 | marketbeat.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comCD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | globenewswire.comTevogen Bio shares surge on revenue forecastApril 29, 2025 | investing.comTevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage AccountsApril 29, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 29, 2025 | globenewswire.comTevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 BillionApril 28, 2025 | globenewswire.comTevogen Bio revises director resignation processApril 27, 2025 | uk.investing.comTevogen Bio past procedure aan voor aftreden bestuurdersApril 26, 2025 | nl.investing.comTevogen Bio Announces 2025 Annual MeetingApril 25, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Tevogen Bio in a report on Monday.April 23, 2025 | marketbeat.comTevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target PredictionApril 18, 2025 | finanznachrichten.deTevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production FacilityApril 17, 2025 | markets.businessinsider.comTevogen Bio Signs Agreement with CD 8 TechnologyApril 17, 2025 | tipranks.comTevogen Bio Secures Agreement with CD8 Technology Services for In-House Cell Therapy Production FacilityApril 17, 2025 | quiverquant.comTevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production FacilityApril 17, 2025 | globenewswire.comTevogen says Databricks commissioned to accelerate PredicTcell developmentApril 16, 2025 | markets.businessinsider.comTevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target PredictionApril 15, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 14, 2025 | globenewswire.comTevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash ConstraintsApril 11, 2025 | seekingalpha.comTevogen announces Tevogen Generics following Trump’s tariff-related statementsApril 10, 2025 | markets.businessinsider.comTevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United StatesApril 9, 2025 | globenewswire.comTevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI BiotechsApril 8, 2025 | globenewswire.comTevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI BiotechsApril 8, 2025 | globenewswire.comTevogen meldt hoog insidersbezit te midden van marktvolatiliteitApril 8, 2025 | nl.investing.comTevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s MissionApril 8, 2025 | markets.businessinsider.comTevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's MissionApril 7, 2025 | globenewswire.com Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Media Mentions By Week TVGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVGN News Sentiment▼0.480.87▲Average Medical News Sentiment TVGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVGN Articles This Week▼103▲TVGN Articles Average Week Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Syndax Pharmaceuticals News Today Collegium Pharmaceutical News Today Enliven Therapeutics News Today Spyre Therapeutics News Today Nurix Therapeutics News Today Niagen Bioscience News Today Ardelyx News Today Avadel Pharmaceuticals News Today Pharvaris News Today CorMedix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVGN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVGN Stock Free TVGN Stock Alerts